DNA2 inhibitors for cancer treatment
Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
1. A compound of formula (B):
wherein X is R 2a -substituted or unsubstituted C 1 -C 8 alkyl, R 2a -substituted or unsubstituted 2-8 membered heteroalkyl, R 2a -substituted or unsubstituted C 3 -C 8 cycloalkyl, R 2a -substituted or unsubstituted 3-6 membered heterocycloalkyl, R 2a -substituted or unsubstituted phenyl, or R 2a -substituted or unsubstituted 5 or 6 membered heteroaryl;
R 2a is independently halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 , —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , —C(CF 3 ) 2 OH, —C(CF 3 ) 3 , unsubstituted C 1 -C 8 alkyl, R 2b -substituted or unsubstituted 2-8 membered heteroalkyl, R 2b -substituted or unsubstituted C 3 -C 8 cycloalkyl, unsubstituted 3-6 membered heterocycloalkyl, or R 2b -substituted or unsubstituted 5 or 6 membered heteroaryl; and
R 2b is independently halogen, —N 3 , —CF 3 , —CCl 3 , —CBr 3 , —CI 3 , —CN, —CHO, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 , —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , —NHC(O)NHNH 2 , unsubstituted C 1 -C 8 alkyl, unsubstituted 2-8 membered heteroalkyl, unsubstituted C 3 -C 8 cycloalkyl, unsubstituted 3-6 membered heterocycloalkyl, unsubstituted phenyl, or unsubstituted 5 or 6 membered heteroaryl;
wherein the compound of Formula (B) is optionally in the form of a pharmaceutically acceptable salt, a tautomer, or a pharmaceutically acceptable salt of a tautomer.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. The compound of claim 1 , wherein:
X is R 2a -substituted or unsubstituted C 1 -C 8 alkyl or R 2a -substituted or unsubstituted phenyl.